ACR335 / Adcoris - LARVOL DELTA

ACR335, a novel cMET/EGFR bispecific dual-payload antibody-drug conjugate, demonstrates potent and broad antitumor activity in preclinical models of solid tumors (AACR 2026) - "Furthermore, ACR335 is engineered as a dual-payload ADC, combining a Topoisomerase I (Top1) inhibitor and a non-Top/non-Tubulin inhibitor, a strategy designed to synergistically maximize tumor cell killing. The BsAb IBR335 combines a fully human anti-cMET antibody (isolated from a naïve phage library) with an engineered version of panitumumab (anti-EGFR). ACR335 is a first-in-class cMET/EGFR bispecific dual-payload ADC with a unique pharmacological profile. The compelling preclinical data underscore its potential as a targeted therapy with an optimized safety profile. Phase I clinical trials are expected to commence in Q2 2026."

ADC • Bispecific • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TOP1